Introduction Pirfenidone, an antifibrotic drug, slows-down the disease progression in idiopathic
pulmonary fibrosis (IPF) over 12 months, however limited data on the decline of lung …

Introduction Prognostic factors of idiopathic pulmonary fibrosis (IPF) currently recognized
include changes in vital capacity and radiologic findings. However, most of the prognostic …

The analysis of an ionic profile of exhaled breath condensate (EBC) by capillary
electrophoresis with contactless conductivity detection and double opposite end injection, is …

Idiopathic pulmonary fibrosis (IPF) is a rare, progressive and usually fatal form of idiopathic
interstitial pneumonia. IPF is characterized by failure of alveolar re-epithelization, persistence …

Aims: Many patients with idiopathic pulmonary fibrosis (IPF) have a delay in diagnosis and
thus also in treatment. We investigated whether such delay influenced survival and treatment …

Most patients with IPF have comorbidities, which affect functional status, quality of life and
survival. Our study aims are to analyze comorbidities in a series of 1210 IPF patients from the …

Aims and objectives: The aim of the study was to compare the annual declineof lung functions
during treatment with pirfenidone in comparison to triple-combination and other treatment …

Ionic analysis of exhaled breath condensate (EBC) offers a simple, non-invasive way of
monitoring nitrosative stress markers and corresponding lung status. The aim was to monitor the …

Popisujeme případ dospělého pacienta, u něhož byla diagnostikována sarkoidóza, a až po
dalších 2 letech byla u téhož pacienta zjištěna i atypická varianta cystické fibrózy. Cystická …

Fourteen patients aged 19 to 38 zears were followed up over 3 years. Genotype/phenotype
correlations were made. Severizy of airway and gastrointerstinal disease was assessed. …